Biotech · Private company · San Diego, CA, US

Avantgen, Inc.

Track this companyFree. Adds Avantgen, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials0None registered

Pipeline programs0None found yet

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

NIH awards4

A novel approach for treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)Fiscal year 2025 · $574.3KNIH RePORTER 5R44CA291331-02 · fetched Nov 12, 2026
Development of rabbit monoclonal antibodies for Ferret biomarkers (Phase II)Fiscal year 2025 · $1.5MNIH RePORTER 75N93025C00013-0-9999-1 · fetched Nov 12, 2026
A novel approach for treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)Fiscal year 2024 · $1.4MNIH RePORTER 1R44CA291331-01 · fetched Nov 12, 2026
DEVELOPMENT OF RABBITMONOCLONAL ANTIBODIES FOR INDIANFLYING FOX (BAT) BIOMARKERSFiscal year 2024 · $592.8KNIH RePORTER 75N93024C00039-0-9999-1 · fetched Nov 12, 2026